BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
   Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%  
THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN ) ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108966974/BLINCYTO-BLINATUMOMAB-ADDED-TO-CHEMOTHERAPY-SIGNIFICANTLY-IMPROVES-SURVIVAL-IN-NEWLY-DIAGNOSED-PEDIATRIC-PATIENTS-WITH-B-CELL-PRECURSOR-ACUTE-LYMPHOBLASTIC-LEUKEMIA-B-ALL
2024-12-07
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
   Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%  
THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN ) ...
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)